Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karl Deres is active.

Publication


Featured researches published by Karl Deres.


European Journal of Immunology | 1998

Ceramide‐independent CD28 and TCR signaling but reduced IL‐2 secretion in T cells of acid sphingomyelinase‐deficient mice

B. Stoffel; Petra Bauer; Michael G. D. Nix; Karl Deres; Wilhelm Stoffel

Ceramide generated by lysosomal acid sphingomyelinase (aSMase) has been proposed to contribute to CD28 co‐stimulatory signaling pathways. We used an aSMase‐deficient mouse line ( asmase − / − ) to elucidate the role of the aSMase in splenocytes stimulated with either a combination of anti‐CD3 and anti‐CD28 antibodies, the lectin concanavalin A (Con A) or the superantigen staphylococcal enterotoxin B. All stimuli were shown to induce IL‐2 expression, Con A additionally triggered the expression of high‐affinity IL‐2 receptor. However, in asmase − / − mice secretion of IL‐2 was significantly reduced, whereas the intracellular IL‐2 levels were elevated. Proliferation of anti‐CD3/anti‐CD28 or Con A‐stimulated aSMase‐deficient splenocytes was reduced up to 50 % after 72 h in comparison to wild‐type cells. We conclude that ceramide generated by aSMase is not involved in CD28 signal transduction, but rather a perturbation of the secretory system is responsible for the impaired proliferation of aSMase‐deficient splenocytes.


Biochemical Pharmacology | 2003

Antivirals interacting with hepatitis B virus core protein and core mutations may misdirect capsid assembly in a similar fashion

Hans Jörg Hacker; Karl Deres; Maria Mildenberger; Claus H. Schröder


Archive | 2001

Medicaments against viral diseases

Siegfried Goldmann; Jurgen Stoltefuss; Karl-Heinz Schlemmer; Jörg Keldenich; Arnold Paessens; Erwin Graef; Olaf Weber; Karl Deres; Ulrich Niewöhner


Archive | 2001

6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viral diseases

Siegfried Goldmann; Jurgen Stoltefuss; Ulrich Niewöhner; Karl-Heinz Schlemmer; Jörg Keldenich; Arnold Paessens; Erwin Graef; Olaf Weber; Karl Deres


Archive | 2001

Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b

Siegfried Goldmann; Jurgen Stoltefuss; Ulrich Niewöhner; Karl-Heinz Schlemmer; Thomas Dr. Krämer; Arnold Paessens; Erwin Graef; Olaf Weber; Karl Deres


Archive | 2000

Dihydropyrimidines and their use in the treatment of hepatitis b

Jörn Stölting; Jurgen Stoltefuss; Siegfried Goldmann; Thomas Dr. Krämer; Karl-Heinz Schlemmer; Ulrich Niewöhner; Arnold Paessens; Erwin Graef; Stefan Lottmann; Karl Deres; Olaf Weber


Archive | 2001

Dihydropyrimidine-5-carboxylic acid esters and use thereof as medicaments against viral diseases

Siegfried Goldmann; Jurgen Stoltefuss; Ulrich Niewöhner; Karl-Heinz Schlemmer; Thomas Dr. Krämer; Arnold Paessens; Erwin Graef; Olaf Weber; Karl Deres


Archive | 2006

3,5-Difluoropyridines

Jürgen Stoltefuβ; Siegfried Goldmann; Thomas Dr. Krämer; Karl-Heinz Schlemmer; Ulrich Niewohner; Maria Theresia Niewohner; Arnold Paeβens; Erwin Graef; Stefan Lottmann; Karl Deres; Olaf Weber; Jörn Stölting


Archive | 2001

Agents pharmaceutiques contre des maladies virales

Siegfried Goldmann; Jurgen Stoltefuss; Ulrich Niewöhner; Karl-Heinz Schlemmer; Jörg Keldenich; Arnold Paessens; Erwin Graef; Olaf Weber; Karl Deres


Archive | 2000

Nouvelles dihydropyrimidines et leur utilisation pour traiter l'hepatite b

Jörn Stölting; Jurgen Stoltefuss; Siegfried Goldmann; Thomas Dr. Krämer; Karl-Heinz Schlemmer; Ulrich Niewöhner; Arnold Paessens; Erwin Graef; Stefan Lottmann; Karl Deres; Olaf Weber

Collaboration


Dive into the Karl Deres's collaboration.

Researchain Logo
Decentralizing Knowledge